Evidence map›Paper›PMID 41909516›Full record

ArticleBlood vessels, thrombosis & hemostasis2026

Real-world avatrombopag use for immune thrombocytopenia in the United States: the REAL-AVA 2.0 multisite chart review study.

Shruti Chaturvedi, Srikanth Nagalla, Scott Kolodny, Abiola Oladapo, Chelsea Bernheisel, Elyse Swallow, Debbie Goldschmidt, Alexandra Greatsinger, Loren Ormenaj, Sinia Sareen and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood vessels, thrombosis & hemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shruti ChaturvediDivision of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Srikanth NagallaMiami Cancer Institute, Miami, FL.
Scott KolodnySobi Inc, Waltham, MA.
Abiola OladapoSobi Inc, Waltham, MA.
Chelsea BernheiselSobi Inc, Waltham, MA.
Elyse SwallowAnalysis Group, Inc, Boston, MA.
Debbie GoldschmidtAnalysis Group, Inc, New York, NY.
Alexandra GreatsingerAnalysis Group, Inc, New York, NY.
Loren OrmenajAnalysis Group, Inc, New York, NY.
Sinia SareenAnalysis Group, Inc, New York, NY.
Jorge Nicolas Ruiz LopezDepartment of Hematology, University of Washington Medical Center and Fred Hutchinson Cancer Research Center, Seattle, WA.
Michael VredenburgSobi Inc, Waltham, MA.
Moshe Yair LevyTexas Oncology, Baylor Charles A. Sammons Cancer Center, Dallas, TX.

Funding

Targeting silent cerebral infarction to improve long-term neurologic outcomes in immune thrombotic thrombocytopenic purpura (iTTP)R00HL172303 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Shruti Chaturvedi · 2024 to 2026
$1.3M
NHLBI NIH HHS R00 HL172303
6 · The paper itself

Abstract

The REAL-AVA 2.0 study was a retrospective multisite chart review evaluating avatrombopag (AVA) effectiveness among patients with primary immune thrombocytopenia (ITP) who underwent routine care in academic- and community-based practices in the United States and initiated AVA between 1 July 2019 and 30 June 2024. Treatment response was defined as achieving platelet counts (PC) ≥30 × 10

Identifiers

PMID41909516
PMCPMC13019542

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.